|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
|
|---|---|---|
| Collaboration revenue | ||
| Operating expenses: | ||
| Research and development | ||
| General and administrative | ||
| Total operating expenses | ||
| Loss from operations | ||
| Other income (expense): | ||
| Interest income | ||
| Change in fair value of long-term investments | ||
| Other expense, net | ||
| Total other income, net | ||
| Net loss before benefit from income taxes | ||
| Benefit from income taxes | ||
| Net loss | ||
| Other comprehensive income (loss): | ||
| Unrealized gain (loss) on available-for-sale marketable securities | ||
| Comprehensive loss | ||
| Net loss per share attributable to common stockholders - basic | ||
| Net loss per share attributable to common stockholders - diluted | ||
| Weighted-average common shares outstanding - basic | ||
| Weighted-average common shares outstanding - diluted |
Loading...
